The Journal of Allergy and Clinical Immunology: In Practice
Review and Feature ArticleThe European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity
Section snippets
Materials and Methods
For each of 92 clinical IEI entities to be verified or excluded in patients who lack a genetic diagnosis, a number of mandatory and suggestive clinical features were defined by international experts and collected between 2013 and 2018. Drafts of proposed criteria were elaborated by experts in the field and were subsequently peer reviewed by 1 or more external experts in the respective category of IEI before implementation. Contributors and reviewers of each entity are stated. A regular quality
Results: Clinical Diagnosis Criteria For Iei And Their Application
The document titled “ESID Registry—Working Definitions for Clinical Diagnosis of PID/IEI” is available in the Online Repository of this article (see Table E1 in this article's Online Repository at www.jaci-inpractice.org) and, in a regularly updated version, on the ESID website.20 Recently, each diagnosis of the compilation was supplemented with OMIM (Online Mendelian Inheritance in Man) numbers of corresponding, genetically defined, diagnosis entities if available, and the respective category
Discussion
The present document describes the development and current version of the ESID Registry Working Definitions for Clinical Diagnosis of PID/IEI as of January 2019, and comprises the entire spectrum of primary immunodeficiencies covered by the ESID registry to date. As it uses clinical disease definitions rather than separate genetic defects, this list may appear shorter than those provided in the IUIS documents. The document was designed to enable correct classification of patients without the
Acknowledgments
The authors would like to thank PPTA (https://www.pptaglobal.org) and its member companies for financial support of the ESID registry.
ESID Registry Working Party members and collaborators are as follows: Mario Abinun, Michael Albert, Sarah Beaussant Cohen, Jacinta Bustamante, Andrew Cant, Jean-Laurent Casanova, Helen Chapel, Genevieve de Saint Basile, Esther de Vries, Inderjeet Dokal, Jean Donadieu, Anne Durandy, David Edgar, Teresa Espanol, Amos Etzioni, Alain Fischer, Bobby Gaspar, Richard
References (21)
- et al.
Exome and genome sequencing for inborn errors of immunity
J Allergy Clin Immunol
(2016) - et al.
History and current status of newborn screening for severe combined immunodeficiency
Semin Perinatol
(2015) - et al.
Modeling strategy to identify patients with primary immunodeficiency utilizing risk management and outcome measurement
Immunol Res
(2017) - et al.
The Duesseldorf warning signs for primary immunodeficiency: is it time to change the rules?
J Clin Immunol
(2015) - et al.
Interdisciplinary AWMF guideline for the diagnostics of primary immunodeficiency [in German]
Klin Padiatr
(2011) - et al.
Ten warning signs of primary immunodeficiency: a new paradigm is needed for the 21st century
Ann N Y Acad Sci
(2011) - et al.
Attending to warning signs of primary immunodeficiency diseases across the range of clinical practice
J Clin Immunol
(2014) - et al.
Use of genetic testing for primary immunodeficiency patients
J Clin Immunol
(2018) - et al.
Newborn screening for primary immunodeficiency diseases: history, current and future practice
J Clin Immunol
(2018) - et al.
TREC based newborn screening for severe combined immunodeficiency disease: a systematic review
J Clin Immunol
(2015)
Cited by (0)
Conflicts of interest: M.G.S. is in part funded by the Styrian Children’s Cancer Aid (Steirische Kinderkrebshilfe) Foundation. S.E. acknowledges support by the Bundeministerium für Bildung und Forschung (BMBF) (01EO1303) and the Deutsche Forschungsgemeinschaft (DFG) (Eh145/9-1 EURO-CID). G.K., R.S., and S.R. acknowledge support by the BMBF (BMBF 01GM0896, 01GM1111B, 01GM1517C, and 01EO1303). B.G. is supported by the German Research Foundation (DFG) under Germany's Excellence Strategy (CIBSS – EXC-2189 – Project ID 390939984) and through the Cluster of Excellence RESIST (EXC 2155; Project ID A2). The rest of the authors declare that they have no relevant conflicts of interest.
- ∗
These authors contributed equally to this work.
- †
These authors jointly coordinated and supervised this work.